Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

M&A activity lifts European shares above 1,000 mark

Published 09/28/2009, 12:28 PM
Updated 09/28/2009, 12:33 PM
UK100
-
BARC
-
BP
-
NOVN
-
SOGN
-
RENE
-
SOLB
-
FERG
-
AZN
-
STAN
-
XRX
-
MS
-
ABT
-

* FTSEurorfirst 300 rises, boosted by M&A deals

* Banks, utilties and drugmakers among top gainers

* German shares rise after elections

* For up-to-the-minute market news, click on [STXNEWS/EU]

By Dominic Lau

LONDON, Sept 28 (Reuters) - European shares rose sharply on Monday, with the main FTSEurofirst 300 <.FTEU3> index regaining the 1,000 mark, as a pick up in merger and acquisition activity buoyed investor sentiment.

U.S. Xerox Corp announced its plan to buy Affiliated Computer Services Inc in a $6.4 billion cash-and-stock deal. [ID:nN2863430]

Abbott Laboratories also said it would buy the drugs unit of Belgium's Solvay in a $6.6 billion deal, while Johnson & Johnson bought an 18 percent stake in Dutch biotech firm Crucell for $444 million.

The FTSEurofirst 300 <.FTEU3> of top European shares closed 1.8 percent higher at 1,001.42 points, snapping a two-day losing streak which pushed the index below the 1,000 level.

"It's a sign that it's getting back to normal and companies are trying to be quick off the mark," said Mark Bon, fund manager at Canada Life in London.

"If you have access to financing at the moment, then the cost of acquisition is quite low because you can buy into a company on low valuations," he said.

Heavyweight banks <.SX7P> were among the top gainers in Europe, with Commerzbank , Barclays , HSBC , Societe Generale and Standard Chartered up 1.7-4.7 percent. The sector has rallied 171 percent since early March.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

However, Norway's biggest banking group DnB NOR lost 2.7 percent, in part due to the country's lifting a ban on short-selling banking and insurance shares and partly in reaction a sharp rise on Friday, a trader said.

Germany's stock market was Europe's strongest performer, with the DAX <.GDAXI> up 2.8 percent after Sunday's election delivered a result that analysts said was helpful to business.

Chancellor Angela Merkel's conservatives vowed to seal a coalition deal, including tax cuts, with the pro-business Free Democrats within a month after winning the election.

POWER UP

Shares in nuclear plant operators E.ON and RWE rose 4.5 and 4.2 percent respectively, driven by investor hopes the German government will reverse a law to close atomic power stations by 2020.

Solar power stocks fell on fears of lower subsidies, with Q-Cells down 1.2 percent.

Among pharmaceutical shares, AstraZeneca advanced 2.8 percent, with traders citing market talk Swiss rival Novartis could be considering a takeover offer. Both AstraZeneca and Novartis, whose shares added 0.9 percent, declined to comment.

Crucell shares sank 3.9 percent as the sale of a stake in the firm to Johnson & Johnson sparked worries that a prospective takeover of the company would not happen, while Solvay shares ticked down 0.1 percent.

Volumes at the FTSEurofirst 300 were at 96 percent of the 90-day average volume.

The pan-European index is up 20.4 percent from its lifetime low of March 9, and is on track to post its best quarterly rise in almost a decade, as investors have become more confident about the prospects of economic recovery.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Across Europe, Britain's FTSE 100 <.FTSE> added 1.6 percent on Monday and France's CAC 40 <.FCHI> put on 2.3 percent.

British building supplies company Wolseley soared more than 11 percent after reporting a full-year profit that beat analysts' expectations. [ID:nLS172820]

Oil producers were also firmer, with BP up 1.9 percent and Royal Dutch Shell rising 2 percent.

A raft of M&A deals also helped shares shrug off weaker data in the United States. A report from the Federal Reserve Bank of Chicago showed economic activity slipped in August, hurt by ongoing weakness in the labour market even as production indicators improved. [ID:nNYS005442]

Morgan Stanley said in a report that equities appeared to be set for a consolidation in the next few weeks but added that an overbought market "has no bearing on the 6-12 month outlook."

"We don't see this (short-term consolidation) as a major turning point so we keep on playing cyclicals/commodities through materials and oil, financials through insurance," Ronan Carr, Morgan Stanley's European equity strategist, said.

(Additional reporting by Brian Gorman and Atul Prakash)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.